

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Nathalie Bamas-Jacques et al.

Examiner: **Tekchand Saidha**

Art Unit: **1652**

Application No.: **10/603,282**

Confirmation No. **4452**

Filed: **June 25, 2003**

Title: **VARIANTS OF THE PAPM
POLYPEPTIDE OF BACTERIA OF
THE STREPTOMYCES GENUS**

CERTIFICATE OF EFS-WEB TRANSMISSION

I hereby certify that the correspondence below is being transmitted via the USPTO's electronic filing system in accordance with 1.6(a)(4), on the date indicated below.

Date of Deposit July 20, 2010

Printed Name of Person

Signing Certificate Delia Coughlin

Signature /Delia Coughlin/

REQUEST FOR CERTIFICATE OF CORRECTION
UNDER 35 U.S.C. 254/255 and 37 C.F.R. 1.322/323

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

The following is a request for a certificate of correction in Serial Number 10/603,282, now patent Number 7,604,970.

A certificate of correction under 35 U.S.C. 254 is respectfully requested in the above-identified patent.

- ☐ All errors were the fault of the USPTO, no fee required. In the event that a further fee is required, please charge the amount to Deposit Account No. **18-1982**.
- ☐ All errors were the fault of the applicant and, accordingly, please charge **\$100.00** to our Deposit Account No. **18-1982**. In the event that a further fee is required, please charge the amount to the same Deposit Account.
- ☒ The errors were the fault of both the applicant and the USPTO and, accordingly, please charge **\$100.00** to our Deposit Account No. **18-1982**. In the event that a further fee is required, please charge the amount to the same Deposit Account.

The exact location where the error appears in the patent and patent application is noted below.

The requested correction is attached on Form PTO 1050.

EXACT LOCATION WHERE ERRORS APPEAR

1. In column 4, line 45-46 (Page 6, Specification, (12/15/2003), line 9): "SEQ D No. 1." should read as - - SEQ ID No. 1. - -.
2. In column 9, line 40 (Page 14, Specification, (12/15/2003), line 22):
"V1/V2=(Vmax1//Km1) [S1]/(Vmax2/Km2) [S2]" should read as - -
V1/V2=(Vmax1/Km1) [S1]/(Vmax2/Km2) [S2] - -.
3. In column 19, line 66-67 (Page 30, Specification, (12/15/2003), line 4-5):
"the-extract" should read as - - the extract - -.
4. In column 23, line 43 (Page 35, Specification, (12/15/2003), line 33):
"kananycin." should read as - - kanamycin. - -.
5. In column 24, line 38 (Page 37, Specification, (12/15/2003), line 13): "KanaR"
should read as - - kanaR - -.
6. In column 26, line 7 (Page 39, Specification, (12/15/2003), line 24):
"PVRC1306" should read as - - pVRC1306 - -.
7. In column 33, line 47-51 (Page 2, Notice of Allowance and Fees Due (PTOL-85), (07/13/2009), Claim 6, line 1-5):
In claim 2, "A nucleic acid comprising SEQ ID NO. 1 modified by mutation for the replacement of at least one of Gly 249 or Thr 192 and optionally modified by the replacement of at least one codon with an alternate codon encoding the same amino acid due to the degeneracy of the genetic code." should read as - - The nucleic acid of claim 1, wherein the polypeptide is modified by mutation of Gly 249 or Thr 192 of SEQ ID NO: 2 with another amino acid; and optionally modified by the replacement of at least one codon in the encoding nucleic acid sequence of SEQ ID NO: 1 with an alternate codon encoding the same modified amino acid at position 249 or 192 due to degeneracy of genetic code.- -.

Respectfully submitted,

/Ann Marie Szczepanik/

Ann Marie Szczepanik, Reg. No. 52,267

Attorney for Applicant

Sanofi-aventis U.S. Inc.
U.S. Patent Operations
Mail Code: BWD-303A
1041 Route 202-206
Bridgewater, New Jersey 08807
Telephone (908) 231-**4757**
Telefax (908) 231-2626
Sanofi-aventis U.S. Docket No. FRAV2002/0013
Date: July 20, 2010